Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy

Satsuki Murakami, Harumi Kato, Yusuke Higuchi, Kazuhito Yamamoto, Hideyuki Yamamoto, Toko Saito, Hirofumi Taji, Yasushi Yatabe, Shigeo Nakamura, Tomohiro Kinoshita

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

Risk stratification of patients with relapsed and refractory follicular lymphoma (FL) remains challenging. Recently, much attention has been paid to the impact of early progression of disease within 2 years of diagnosis (early POD) on subsequent survival. The aim of this study was to clarify the clinical features and prognostic factors of patients with FL who experienced early POD. Data were available for 94 patients diagnosed with FL (clinical stage II–IV) who had received immunochemotherapy. Early POD was seen in 20 % of these patients. The Cox proportional hazards model showed worse overall survival (OS) in the patients with early POD compared with those without early POD (5-year OS rates 48 % vs. 96 %, P < 0.0001). In multivariate analysis, early POD (P = 0.003) and poor performance status (P = 0.006) remained a significant factor for subsequent OS. In Follicular Lymphoma International Prognostic Index (FLIPI)- and Follicular Lymphoma International Prognostic Index-2 (FLIPI2)-adjusted Cox regression analysis, early POD was associated with markedly reduced OS with a hazard ratio of 11.2 [95 % confidence interval (CI) 3.13–40.3, P < 0.001] and 13.5 (95 % CI 3.22–56.3, P < 0.003), respectively. Among patients who had early POD, high levels of serum lactate dehydrogenase (LDH) both at the time of initial diagnosis and first progression could be associated with worse survival (2-year OS rates 33 vs. 92 %, P < 0.0001). Evaluation of LDH levels at the time of initial diagnosis and first progression may be important to define patients who were associated with worse prognosis. Risk stratification of patients with early POD could lead to improved clinical outcomes for FL patients. Further research is needed to investigate its value for decision making.

Original languageEnglish
Pages (from-to)1259-1269
Number of pages11
JournalAnnals of Hematology
Volume95
Issue number8
DOIs
Publication statusPublished - 01-08-2016
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Hematology

Fingerprint Dive into the research topics of 'Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy'. Together they form a unique fingerprint.

Cite this